• Profile
Close

Low-dose imipramine for refractory functional dyspepsia: A randomized, double-blind, placebo-controlled trial

The Lancet: Gastroenterology & Hepatology Dec 12, 2018

Cheong PK, et al. - The researchers assessed the safety and efficiency of imipramine, a tricyclic antidepressant (TCA), in the treatment of functional dyspepsia between Sept 11, 2005, and Aug 20, 2010, in 107 Helicobacter pylori-negative individuals. It was assumed that low-dose imipramine should be regarded as a possible medicine for subjects with functional dyspepsia not responding to proton pump inhibitors (PPIs) and prokinetics. Mild adverse effects eg, dry mouths, constipation, drowsiness, insomnia, palpitations, and blurred vision were also observed.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay